Cell and Tissue Research

, Volume 373, Issue 1, pp 297–312 | Cite as

Lateralisation in Parkinson disease

  • P. Riederer
  • K. A. Jellinger
  • P. Kolber
  • G. Hipp
  • J. Sian-Hülsmann
  • R. Krüger


Asymmetry of dopaminergic neurodegeneration and subsequent lateralisation of motor symptoms are distinctive features of Parkinson’s disease compared to other forms of neurodegenerative or symptomatic parkinsonism. Even 200 years after the first description of the disease, the underlying causes for this striking clinicopathological feature are not yet fully understood. There is increasing evidence that lateralisation of disease is due to a complex interplay of hereditary and environmental factors that are reflected not only in the concept of dominant hemispheres and handedness but also in specific susceptibilities of neuronal subpopulations within the substantia nigra. As a consequence, not only the obvious lateralisation of motor symptoms occurs but also patterns of associated non-motor signs are defined, which include cognitive functions, sleep behaviour or olfaction. Better understanding of the mechanisms contributing to lateralisation of neurodegeneration and the resulting patterns of clinical phenotypes based on bilateral post-mortem brain analyses and clinical studies focusing on right/left hemispheric symptom origin will help to develop more targeted therapeutic approaches, taking into account subtypes of PD as a heterogeneous disorder.


Parkinson’s disease Parkinsonism Asymmetry Lateralisation Dopamine Handedness Genetics 




atypical Parkinsonian Syndrome






depression anxiety stress scales


definite suicidal behaviour




dopamine transporter


fluorine-18-labelled fluorodopa


Diffusion Tensor Imaging






Help Advance Luxembourg’s Parkinson Research Study


Lewy body


locus coeruleus


left-dominant Parkinson’s disease


Lewy body dementia


late-onset Parkinson’s disease


leucine-rich repeat kinase 2


International Parkinson and Movement Disorder Society


magnetic resonance imaging


multiple system atrophy


multiple system atrophy-type parkinson


Montreal Cognitive Assessment






olfactory bulb




Parkinson’s disease


Parkinson’s disease with dementia


progressive supranuclear palsy


positron emission tomography


preformed fibrils


rapid eye movement


right-dominant Parkinson’s disease


raphe nucleus


substantia nigra


substantia nigra pars compacta


single-photon-emission computed tomography


tyrosine hydroxylase


United Parkinson’s Disease Rating Scale


young-onset Parkinson’s disease

Clinical evidence of asymmetry

Parkinson’s disease (PD) is an asymmetric condition compared to other degenerative parkinsonisms, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP) or Lewy body dementia (LBD) and a certain degree of the asymmetry is typically maintained throughout the course of the disease (Baumann et al. 2014; Counihan and Penney 1998; Cubo et al. 2010; Djaldetti et al. 2006; Fearnley and Lees 1991; Hughes et al. 1992; Kish et al. 1988). The underlying motor symptoms are primarily related to the loss of dopamine in the basal ganglia (Yagi et al. 2010), which occurs bilateral but only around 16.4% of PD patients show symmetric motor symptoms, compared to 48.3% of the MSA-P and even 52.9% of the PSP patients (Gómez-Esteban et al. 2010) corresponding to a more symmetric involvement of cortical and subcortical degeneration in MSA and PSP (Amtage et al. 2014). In a large clinical series of 1277 individuals diagnosed with PD, 46% met criteria for asymmetric disease, associated with a shorter disease duration, younger age at symptomatic onset, asymmetrical initial symptom onset, hand dominance and a positive self-reported family history of “other” neurodegenerative disorders. Hand dominance was related to the side of asymmetric disease such that left-handed individuals tended to have more severe disease on the left side of the body (Uitti et al. 2005). In patients with MSA-P, putaminal atrophy was frequently observed (14/27 cases, 51.9%) and was most commonly found in the unilateral putamen (13/14 cases). Marked signal hypointensity was observed in 12 patients with MSA-P (44.4%). No patients with idiopathic PD or healthy controls showed putaminal atrophy or marked signal hypointensity. Quantitatively measured putaminal width, phase-shift values and the ratio of mean phase-shift values for the dominant and nondominant sides were significantly different between the MSA-P group and the idiopathic PD and healthy control groups (p < 0.001) (Hwang et al. 2015). However, a few cases of MSA-P can initially present with marked asymmetric parkinsonism and rigid dystonic limb posturing leading to a diagnosis of corticobasal syndrome at onset (Batla et al. 2013). Asymmetry of clinical features is a common finding in PD and many patients have not only unilateral motor symptoms but also non-motor deficits (Djaldetti et al. 2006; Tang et al. 2010) at the time of onset, while asymmetry may become less prominent over the course of the disease (Nandhagopal et al. 2009). In early PD, the lateralisation of brain activity during unilateral movement is significantly reduced, the disruption of the lateralised brain activity pattern may be a reason underlying some motor deficits, like mirror movements or impaired bilateral motor coordination (Wu et al. 2015). The motor asymmetry observed in PD may serve as a clinical parameter to differentiate PD from other parkinsonian syndromes (Brooks and Pavese 2009). Indeed, clinical asymmetry in PD can be even found at later stages of the disease, with more marked extrapyramidal involvement on the body side first affected (Kempster et al. 1989).

Also, in the recently established Parkinson cohort in Luxembourg (Hipp 2015), the vast majority of the recruited PD patients had initially unilateral symptoms. Out of 352 patients with PD or PD with dementia (PDD), 87.5% had as initial symptom unilateral (left or right sided) tremor, 69.7% unilateral rigidity and 66.4% unilateral bradykinesia. Absolute numbers were much lower for the atypical parkinsonian syndromes (aPS) due to their rarity but also showed a trend towards a unilateral initiation of symptoms. After a mean disease duration of 9.08 ± 7.37 years, tremor was asymmetric in 84.3% of the patients with aPS and rigidity and bradykinesia asymmetric in 58.6% and 54.7% of the patients, respectively. This trend was more pronounced in aPS, where after a mean disease duration of 5.59 ± 5.71 years, asymmetric symptoms are only 41% of the patients for bradykinesia and 55.2% for rigidity (but 72.9% for tremor). This underlines that idiopathic PD has typically a unilateral disease onset but it tends to become symmetric after several years of disease duration, especially in bradykinesia and rigidity. Compared to healthy individuals, patients with PD usually exhibit greater asymmetry while performing tasks requiring postural control (Beretta et al. 2015).

The typical asymmetry of clinical symptoms at disease onset is observed not only in the common sporadic form of PD but also in monogenic forms of the disease (Djaldetti et al. 2006; Riederer and Sian-Hülsmann 2012), although the mechanism of the initial unilaterality of symptom appearance is poorly understood (Martinu et al. 2014). There is only sparse information about whether such unilaterality is genetically encoded or whether it is acquired and related to side differences in vulnerability of the degenerating neurons (Djaldetti et al. 2006). Many hereditary types of PD appear to be typical in terms of the initial unilaterality and subsequent bilateral with dominant side phenotype (Doherty et al. 2013; Houlden and Singleton 2012; Kiely et al. 2015; Neumann et al. 2009; Schiesling et al. 2008). Indeed, the asymmetry of radioligand uptake in PD associated with glucocerebrosidase (GBA) or leucine-rich repeat kinase 2 (LRRK2) mutations supports that also genetic forms of PD present with asymmetry and indicates that genetic or environmental factors may be associated with dopaminergic neuron loss (McNeill et al. 2013). Asymmetrical onset was also reported in the majority of patients with Parkin mutations (Lohmann et al. 2003a, b).

Handedness and side of motor onset

It has been suggested that the side of onset of initial motor symptoms of PD and the dominant hand are independently related (Amick et al. 2006; Jellinger 2014; Yust-Katz et al. 2008). PD symptoms emerge more often on the dominant-hand side and the dominant side of symptoms is usually in accordance with handedness (Barrett et al. 2011; Shi et al. 2014; van der Hoorn et al. 2012).

In this context, PD symptoms emerge more often on the dominant hand side, probably due to an increased nigrostriatal dopamine turnover in the dominant hemisphere supported by in vivo measurements with PET, even suggesting to find asymmetric dopamine cell count (Klawans 1972; de la Fuente-Fernández et al. 2000; van der Hoorn et al. 2012).

Tremor, bradykinesia and akinesia are the cardinal features of PD and it appears that lateralisation of motor symptoms may be related to non-motor symptoms. Here, it has been initially reported that right-sided onset of tremor (and other motor dysfunctions) is related to a better cognitive function compared to left-sided onset (Direnfeld et al. 1984; Tomer et al. 1993). Recent studies found that PD patients exhibiting a more marked left hemisphere motor dysfunction exhibited greater cognitive impairment (Hanna-Pladdy et al. 2015). Vice versa left-sided onset and left-handedness were related to a more benign disease course (Munhoz et al. 2013). The degree of motor dysfunction does not determine the severity of cognitive impairment; the latter appears to depend on the basal dopamine levels. Interestingly, in the healthy brain, the left hemisphere boosts a greater striatal dopamine content than the right; thus, the brain appears to present with an uneven distribution of dopamine content (Brichta and Greengard 2014). This may confer susceptibility of the nigro-striatal tract to degenerate, particular in the presence of a trigger factor(s) responsible for causing the disease. Indeed, a recent study showed that an increased dopamine metabolism is critically related to oxidation, lysosomal dysfunction and finally neurodegeneration and even explains the species-specific degeneration of dopaminergic neurons from humans with PD (Burbulla et al. 2017)

Side of motor onset and non-motor symptoms

Interestingly, Amick et al. (2006) found that the side of motor onset is related to differential patterns of cognitive impairment. PD patients with right-side motor symptom predominance present more difficulties in tasks of language and verbal memory, whereas those with left-side motor symptoms present more difficulties in visuospatial tasks, indicating that the side of clinical motor predominance influences cognition suggesting that cognitive differences between subgroups of lateralised PD patients may appear in more advanced disease stages (Poletti et al. 2013; Pellicano et al. 2015). Recent data suggest that the onset of asymmetric motor symptoms in PD may be associated with hemisphere-specific memory decline and lateralised grey matter loss, particularly in left-dominant PD (LPD). This underscores the importance of classifying PD subgroups based on the side of motor symptom onset for clinical care and research to optimize cognitive outcomes (Riederer and Sian-Hülsmann 2012; Lee et al. 2015). Patients with motor onset on their dominant side show significantly fewer motor deficits than non-dominant-side ones, suggesting that the first group has a greater neural reserve allowing them to better cope with PD-related changes (i.e., fewer motor deficits despite similar dopamine reduction), i.e., better motor compensation (Ham et al. 2015). Other studies support a direct involvement of the asymmetry of gait in the development of freezing of gait in PD (Frazzitta et al. 2013).

Schendan et al. (2009) linked side of motor symptom onset to visuospatial cognitive abilities that depend upon the contralateral posterior temporoparietal junction and highlighted that side of onset can predict visuospatial impairments. Using normative neuroimaging and neuropsychology, an individual diagnosed with PD had been described, finding striking striatal asymmetry followed secondarily by cortical thickness asymmetry and possible frontal white matter asymmetry. This decline and variability in visual working memory could be linked to ongoing atrophy of his right caudate nucleus (Tanner et al. 2017). It has been hypothesized that inhibitory control relies upon a right-lateralized pathway and it was tested whether LPD patients suffered from a more severe deficit in this key executive function than right-dominant PD (RPD) patients. In an assessment of both proactive and reactive inhibition in 20 LPD, 20 RPD and 20 age-matched healthy subjects, PD patients were significantly more impaired in both forms of inhibitory control than healthy subjects. However, there were no differences either in reactive or proactive inhibition between LPD and RPD patients. All in all, these data support the idea that brain regions affected by PD play a fundamental role in subserving inhibitory function but do not sustain the hypothesis according to which this executive function is predominantly or solely computed by the brain regions of the right hemisphere (Mirabella et al. 2017). Compromised executive function in LPD and greater anxiety on the DASS Anxiety scales and lower magical ideation were separated by Modestino et al. (2017). However, this increased anxiety—in contrast to Foster et al. (2008)—could not account for the poorer performance on the DSB for left-onset PD (Modestino et al. 2017). PD patients show a higher anxiety level than controls. In LPD, apathy but not anxiety was associated with performance on non-verbally mediated executive function and visuospatial measures, whereas, in RPD, anxiety but not apathy correlated with performance on verbally mediated task (Bogdanova and Cronin-Golomb 2012). Motor-symptom laterality could affect feedback-based associative learning in PD, with left-onset medication-naive patients being selectively impaired. Dysfunction in the right dorsal rostral putamen may underlie the observed deficit in associative learning in patients with left-sided onset (Huang et al. 2017).

The first results of the HELP-PD cohort in Luxembourg (Hipp 2015) seem to provide hints that right-handed PD and PDD patients with contralateral onset of their motor symptoms (on their non-dominant body side; N = 86) tend to have a slightly higher MDS-UPDRS-III of 30.84 ± 15.04 and more motor complications (MDS-UPDRS-IV 2.20 ± 3.45) but having less repercussions on activities of daily life with an MDS-UPDRS-I of 9.64 ± 7.16 and MDS-UPDRS-II of 10.54 ± 7.69, compared to patients with right-handed motor onset of their symptoms (N = 77) with MDS-UPDRS-I, II, III and IV scores of 10.73 ± 6.79, 12.38 ± 8.75, 29.13 ± 17.94 and 1.87 ± 3.10, respectively). The cognitive function measured with the MOCA score was slightly better in right-handed patients with a disease onset on their non-dominant side (24.91 ± 3.99 vs. 24.26 ± 3.85). The difference was even greater in right-handed patients with predominant right hemispheric symptoms (N = 112) compared to those having motor symptoms predominantly from the left hemisphere (N = 132; MDS-UPDRS-III 33.89 ± 15.08 vs 30.70 ± 18.76). Cognitive function seems to be similar (MOCA 24.31 ± 4.28 vs 24.36 ± 4.55) between both groups of right-handed patients. Of course, these trends need still to be verified after completion of patient recruitment of the HELP-PD cohort but seem to indicate that the non-dominant right hemisphere is more vulnerable in right-handed patients. On the other hand, in early PD, the side of onset of motor symptoms did not seem to influence neuropsychiatric and cognitive symptoms (Pellicano et al. 2015), which was debated by Erro et al. (2015).

Early disease onset, left-handedness and left-side onset are associated with long disease and ambulatory PD survival (Munhoz et al. 2013; Modestino et al. 2017) but also increased frequency of REM sleep behavior disorder (Baumann et al. 2014), while left motor dysfunction and smaller right substantia nigra (SN) volume were associated with poorer spatial memory (Foster et al. 2008). A nationwide longitudinal and multicenter study showed that right-onset PD had higher psychosis rating scales over time compared with left-onset PD but no significant differences were observed for other non-motor symptoms (Cubo et al. 2010). Olfactory dysfunction in early PD is robust, typically of the same general magnitude on both sides and uninfluenced by anti-Parkinson medication (Doty et al. 1992), whereas according to others, there is more olfactory sensitivity contralateral to the more affected side of the body (Zucco et al. 2001) and hemihyposmia was reported in a case of hemiparkinsonism (Heckmann et al. 2004). This appears of interest, because olfactory dysfunction is a very early symptom in PD in contrast to other forms of parkinsonism (Attems et al. 2014; Wenning et al. 1995). This is suggested to result from a complex network dysfunction that exceeds the pathology of the olfactory bulb and mesolimbic cortices (Attems et al. 2014; Moessnang et al. 2011). Rey et al. (2016) recently demonstrated that pathology induced by unilateral injection of human or mouse wild-type α-synuclein (αSyn) pre-formed fibrils (PFFs), designated huPFFs or mPFFs, respectively, into the olfactory bulb (OB) of 3-month-old wild-type (WT) mice can propagate sequentially over multiple synaptic relays, reaching numerous ipsi- and contralateral brain regions after 12 months, including brain stem areas (e.g., a few aggregates in the SN, locus coeruleus (LC) and raphe nucleus (RN)). The spreading of α-syn aggregates was coupled to progressive deficits in olfaction. Of particular interest is the notion that in a meta-analysis both the left and the right OB volume were significantly smaller in PD than in healthy controls (Li et al. 2016). However, right-sided PD performed worse with the left nostril, while no nostril-related differences were observed in controls (Zucco et al. 2015).

In agreement with Hobson (2012), this points to the conclusion that asymmetry in PD results from a greater susceptibility of SN in one hemisphere. Another possibility would be an initiation of spreading pathology that starts on one side and subsequently involves the other side (Hobson 2012). For example, presynaptic modulation of olfactory sensory neurons by local interneurons as a mechanism for gain control, cell class specific effects of serotonergic centrifugal neurons on olfactory processing or the integration of intrinsic and extrinsic neuromodulation are important control mechanisms of olfactory network dynamics (Lizbinski and Dacks 2018; Sun et al. 2017). In addition, genetic alterations may contribute to the asymmetry as seen in PD.

Notably, the studies of Park et al. (2018) demonstrated that in patients with PD plus MCI the olfactory dysfunction was more prominent compared to PD without cognitive disturbances, pointing to more extensive or multiple pathologies underlying olfaction in patients with PD plus MCI (Park et al. 2018; Lizbinski and Dacks 2018).

In the gastrointestinal tract left-sided vagal innervation of the stomach/cardiac and right-sided vagal innervation of the small intestine and proximal part of the colon has been described (Standring and Gray 2008). However, there is so far no evidence that these asymmetries contribute to the pathology of PD. In the experimental studies of Pan-Montojo et al. (2010) using systemic applications of rotenone into the gastrointestinal tract, parkinsonism was shown to be bilateral. Therefore, it is of importance to design experimental studies with the focus on asymmetries.

Histopathological evidence for asymmetric dopaminergic cell loss in brain

In sporadic PD, the essential neuropathology is considerable neuronal loss in the DAergic substantia nigra compacta (SNc) associated with Lewy body (LB)/αSynuclein pathology involving the central and peripheral nervous system and multiple organs (Beach et al. 2010; Jellinger 2012, 2014). Stereological analyses of the number of SN neurons, performed only on one side (unilaterally) found significant loss of pigmented (− 28.3%) and TH+ (− 36.2%) neurons in older versus younger healthy subjects but up to 70-80% cell loss with significant atrophy of pigmented nigral neurons in end-stage PD patients (Rudow et al. 2008), while others reported reduction of SN neurons in PD by 66% compared to controls (Pakkenberg et al. 1991). Earlier studies reported midbrain DAergic neuron loss in PD brains of around 50% of healthy controls, in area A 8 and 9 (− 61%) and ventral tegmental area A 10 (− 48%) (German et al. 1989). Cell loss in the SN is not uniform, preferentially affecting regions with synaptic connection to the putamen (Hassler 1938). Thus, the degree of asymmetry in the regions of the SN may be greater than is suggested by whole nigral cell counts. The most severe depletion involves the nigrosome 1, located in the caudal and mediolateral tier of SNc, projecting to the striatum and spreading along a caudo-rostral, latero-medial and ventro-dorsal progression (Damier et al. 1999). This temporo-spatial disorder corresponds to a somatotopic pattern of DAergic terminal loss in the dorsal and caudal putamen, with later involvement of the ventral putamen and caudate nucleus (Kish et al. 1988). Recent 7T MRI studies allowed for the visualization of the nigrosome 1 as a hyperintensive signal in the SNc of healthy subjects (“swallow tail sign”) and its absence in PD patients, probably because of the loss of melanized neurons and the increase of iron deposition in degenerated SN (Lehéricy et al. 2014).

A clinico-pathological study of 21 PD cases (age at onset 39–73; mean 57 ±9 years; duration 4–23, mean 13.7 ± 8 years) showed considerable asymmetry of the mean nigral neuronal count with a 25% reduction in the SN contralateral to the initially more affected body side, thus providing pathological confirmation for the predominantly unilateral motor manifestation (Kempster et al. 1989). To the best of our knowledge, no other bilateral numeric SN cell counts are available. Further post mortem studies provided support for the occurrence of DA asymmetry (Glick et al. 1982; Toga and Thompson 2003). The right hemisphere appears to have lower levels of DA compared to the left, which may in turn confer susceptibility to dopaminergic degeneration. Alternatively, this neurochemical lateralisation may compromise the plasticity of the right hemisphere in the disease process in PD. Eventually, the progressive neurodegeneration of the SN leads to the manifestation of motor symptoms characteristic of the illness. Data on asymmetry of non-dopaminergic systems in PD, to the best of our knowledge, are currently not available.

Given the extent of preclinical dopaminergic denervation (Tissingh et al. 1998), it is conceivable that compensatory changes extend also beyond the nigrostriatal portion of the motor circuit. Patients with clinically asymmetric PD represent a valuable model to study compensatory reorganisation within the motor system since functional changes that prevent motor symptom progression are likely to be more evident on the less affected side. A previous [18F]-fluorodeoxyglucose PET study provided little evidence that this might be the case. Asymmetric patients had an equally abnormal metabolic pattern in cortex and subcortical structures of both hemispheres (except within the putamen) (Tang et al. 2010). However, an apparent absence of metabolic asymmetry in the sensorimotor cortex, a major output of basal ganglia–cortical loops, could reflect insufficient sensitivity of metabolic measures. Increased motor cortical plasticity on the less affected side is consistent with a functional reorganisation of the sensorimotor cortex and may represent a compensatory change that contributes to delaying onset of clinical symptoms. Alternatively, it may reflect a maladaptive plasticity that provokes symptom onset. Plasticity deteriorates as the symptoms progress, as seen on the more affected side (Kojovic et al. 2012).

The motor symptoms are exhibited after a marked loss of the nigral neurons resulting in a consequent depletion of the striatal dopamine especially at the side of disease onset. Thus, the ability of the nigro-striatal motor pathway to compensate in spite of the marked cell loss illustrates the remarkable robustness of the system (Bernheimer et al. 1973). Perhaps, the preclinical phase may illustrate a gradual rate of destruction of nigral dopaminergic neurons, preferring one side at the very begin of disease onset. Compensation is suggested to show a higher degree on the more affected side. Laterality of nigrosome 1 was in concordance with clinical laterality. Unilateral symptomatology in PD corresponds to neuronal nigrostriatal degeneration in the contralateral hemisphere; the abnormality of nigrosome 2 can be detected at 3T and 7T MRI with an accuracy of 94.6% (Noh et al. 2015). In PD, the lateral surface of the SN presents an undulated aspect, which predominates in the more severely affected hemisphere (contralateral to the more severe clinical symptoms (Kwon et al. 2012; Lehéricy et al. 2014). Striatal DA loss significantly correlates with loss of DAergic SN neurons (Bernheimer et al. 1973) but neither αSyn nor ß-amyloid (Aβ) deposition (Colloby et al. 2012). Dopamine transporter (DAT) immunoreactivity in the striatum is inversely correlated with the total αSyn burden but not with the Lewy body counts nor the SN, which supports the concept of synaptic dysfunction or impairment of axonal transport of αSyn aggregations (Kovacs et al. 2008). Whether the distribution of LB, as an index of abnormal α-syn deposition and pathological hallmarks of PD, may influence the lateralisation of PD is unknown (Djaldetti et al. 2006).

DA markers in dorsal putamen show mild (around 10%) loss one year after clinical diagnosis but 50–90% TH+ neuron loss at 4 years, loss of melanized SN neurons lagging behind the loss of striatal DA markers (Kordower et al. 2013). However, recent SPECT studies indicated that degeneration of the dopaminergic system is not total, even after many years of illness, the loss being more prominent in the putamen than in the caudate nucleus (Djaldetti et al. 2011). Around 12% nigral cell loss was already observed before αSyn aggregation and increased to 46% at Braak Lewy stages 3 and 4 (Dijkstra et al. 2014).

Unilateral patients display 20% of abnormal αSyn deposits in the C7 paravertebral spinal regions contralateral to the clinically more affected (motor) side, 60% in both sides and 20% in the non-affected side (Donadio et al. 2017),

The striatal DA transporter (DAT) binding in 5 cases of LB disorders (2 PD, 3 DLB) moderately correlated with the asymmetry of DAergic degeneration in the SNc, based on the number of neuromelanin-containing neurons (r = 0.76; p = 0.028) (Kraemmer et al. 2014). DAT imaging in 14 autopsy-confirmed cases of PD (n = 8) and MSA (n = 6), demonstrated that mean overall striatal DAT binding was reduced by 52% in PD and 53% in MSA, with a greater trend for asymmetry of striatal binding in MSA compared to PD (23 ± 15 vs 10.5 ± 7%, respectively; p = 0.71), with 3 MSA patients showing more asymmetry of striatal DAT binding than any PD patient (Perju-Dumbrava et al. 2012), whereas others found less asymmetric striatal ß-CIT binding in 26 clinical MSA compared with 157 PD patients (Varrone et al. 2001) and more asymmetry of striatal β-CIT binding in clinical cases of PD than in MSA (Knudsen et al. 2004).

The majority of clinico-pathological studies of PD staging protocols and morphological reviews (Braak et al. 2003; Braak and Del Tredici 2008; Halliday and Murphy 2010; Jellinger 2012) as well as recent MRI and PET studies on basal ganglia and nigrostriatal function in PD (Péran et al. 2010; Perlmutter and Norris 2014; Rolinski et al. 2016) did not consider lateralisation or asymmetry of the motor symptoms and, to the best of our knowledge, there are only few such studies considering clinical and morphological lateralisation. Evidence for an asymmetry of this neurodegenerative process was first provided by Barolin et al. (1964), who reported a reduction in striatal DA content contralateral to the most affected body side in a case with PD. Among 20 neuropathologically and biochemically studied cases of PD, five (aged 66–82; mean 75 years; disease duration 4–12; mean 5.5 years), showed asymmetrical clinical symptoms, which were associated with different severities of neuronal loss in various parts of the SN, although side differences of the dopaminergic striatal system were not measured (Bernheimer et al. 1973). The same holds true for recent MRI studies of the SN in PD (Prasad et al. 2018).

Neuroimaging-based evidence for asymmetric dopaminergic neurodegeneration

SPECT and PET studies of fluorine-18-labelled fluorodopa (18 F-DOPA) assessing the integrity of the presynaptic nigrostriatal system show reduced tracer uptake in the posterior putamen contralateral to the predominantly affected side as an almost pathognomic sign for PD (Leenders et al. 1990; Rinne et al. 1993; Snow et al. 1993; Bohnen et al. 2006; Kaasinen 2015). Shape analysis in de novo PD patients using DAT SPECT suggested a progressive medial-to-lateral involvement of the putamen that paralleled an asymmetric-to-bilateral distribution of DAT depletion (Caligiuri et al. 2016). Asymmetric scans are observed not only in early forms with mild symptoms but also in prodromal asymptomatic cases who developed parkinsonian symptoms years after detection by imaging (Laihinen et al. 2000). PET studies in young (YOPD) and late onset PD (LOPD) cases showed that the caudate/anterior putamen ratios were significantly higher in YOPD than that in the LOPD (p = 0.03 contralateral to the most affected side of the body and p = 0.004 ipsilateral), which was supported by significantly inverse correlations between age of onset and caudate/anterior putamen ratios (r = − 0.428, p < 0.001 for the contralateral and r = − 0.576, p < 0.001 for the ipsilateral). Sub-regional DAT binding in the caudate ipsilateral to affected limbs was significantly correlated with age, while DAT bindings in putamen were significantly inversely correlated with disease duration and UPDRS motor scores (Liu et al. 2015). Patients with unilateral onset increase contralateral to the most clinically affected side, i.e., in the most damaged side (Kumar and Mandal 2003).

FDG-PET studies demonstrated inverse asymmetry of basal ganglia glucose metabolism in PD patients (Dethy et al. 1998) and 18-FDOPA PET showed biochemical asymmetry in the caudate and putamen in early PD, correlating with asymmetry of motor symptoms (Kumakura et al. 2006). This pattern of asymmetry generally remains unaltered during disease progression (Benamer et al. 2000).

PET studies showed lateralisation of DAergic function in that right caudate 18F-DOPA uptake selectively covariated with certain memory performance tasks and left putamen 18F-DOPA uptake with performance on verbal working memory tests, indicating that subcortical structures may be important mediators of lateralised hemispheral functions (Cheesman et al. 2005). 18F-DOPA uptake studies showed that in PD but not in controls, reaction time is inversely related to the levels of DA in the left lateral orbitofrontal cortex (Marinelli et al. 2015).

The lateralisation of brain activity pattern during right-hand movement is weakened, and the left dominance of lateralisation is reduced but shows a tendency to bilateral dominance; this supports a neuroprotective effect of enhanced physical activity by handedness on the contralateral motor cortex (Kim et al. 2014). On the other hand, β-CIT SPECT imaging demonstrated bilateral loss of striatal DAT by approximately 53% contralateral and 38% ipsilateral to the clinically symptomatic side in hemi-PD patients (Marek et al. 1996). However, the preponderance of reduced left putaminal DAT availability strengthens the clinical observation of a greater proportion of right-handed PD patients with predominantly right-sided motor signs and argues against a randomly distributed asymmetric vulnerability of SN DAergic neurons (Erro et al. 2013; Hoshiyama et al. 2015. The fact that right-handed PD patients had predominant right-sided motor symptoms and left-sided DA deficits, whereas the effect was opposite in left-handed patients (p = 0.005 and 0.028, respectively), suggested that the side of DAergic deficits in PD are not random but are directed by brain lateralisation (Kaasinen 2015). A meta-analysis previously provided evidence of the association between the predominant side of PD symptoms and hand dominance (van der Hoorn et al. 2012). A subgroup of right-handed PD patients with more severe and predominant ipsilateral DAT decline suggests that asymmetry of DAergic denervation and motor dysfunction in PD cannot be fully explained by hemispheric dominance alone but that other factors may also be involved, that, however, needs further elucidation (Scherfler et al. 2012). Other recent functional MRI studies in early PD patients showed the lateralisation of brain activity during unilateral right-hand movement to be weakened. The left dominance of lateralisation was significantly reduced but showed a tendency to bilateral dominance (Wu et al. 2016). Motor asymmetry and SN volume changes have been shown to be related to spatial response performance in PD (Foster et al. 2009).

Recent 18F-flortaucipir PET studies in PD patients have consistently shown no increased tau binding in the basal ganglia or in the cerebral cortex (Gomperts et al. 2016; Hansen et al. 2016; Lee et al. 2018; Schonhaut et al. 2017). PD patients exhibited approximately 13% lower 18F-flortaucipir tau-binding in the substantia nigra compared to controls (Hansen et al. 2016; Schonhaut et al. 2017), due to off-target binding of 18F-flortaucipir to neuromelanin pigment, which normally exists in the substantia nigra and is lost in PD (Lowe et al. 2016; Marquié et al. 2015). Reduced 18F-flortaucipir tau-binding was more prominent in the lateral part of the substantia nigra than in the medial part. However, nigral 18F-flortaucipir tau-binding did not correlate with the motor severity of PD and did not reflect clinical asymmetry (Hansen et al. 2016).

Modern MRI methods (transverse relaxation mapping and DTI) demonstrated significant differences between the symptomatic and non-symptomatic hemispheres, in particular fractional anisotropy and mean diffusivity in the putamen in early-onset PD, supporting the hypothesis of asymmetric neurodegeneration in the bilateral nigrostriatal pathways emerging already in the early stage of the disease (Wang et al. 2015). Functional MRI investigation of the lateralisation brain activity patterns during performance of unilateral movement in drug-naive PD patients with only right hemiparkinson symptoms showed decreased activity in the left putamen and left supplementary motor area but increased activity in the right primary motor and premotor cortex, left post-central gyrus and bilateral cerebellum. The connectivity from the left putamen to motor cortex regions and cerebellum was decreased, while interactions between the cortical motor regions, cerebellar and right putamen were increased. This study demonstrated that in early PD, the lateralisation of brain activity during unilateral movement is significantly reduced. The dysfunction of the striato-cortical circuit, decreased transcallosal inhibition and compensatory efforts from cortical motor regions, cerebellum and the less affected striatum are likely reasons contributing to the reduced motor lateralisation (Wu et al. 2015). Volumetric analysis of SN volume asymmetry showed poor agreement with clinical asymmetry in 60 patients with PD (Durmaz et al. 2016), while iron-related MRI contrast asymmetry in SN was higher in PD than in controls (Gorell et al. 1995). More recent MRI studies found a significant correlation between asymmetric motor features in PD and T1ρ relaxation time in SN, which is sensitive to cellular changes and the presence of iron (Nestrasil et al. 2010). Recent MRI studies of the posterior SN revealed a lateral asymmetry and spatial difference of iron deposition in the more affected hemibrains than in controls (p < 0.05) (Azuma et al. 2016). Of interest is a finding of Xu et al. (2008) showing that there is a hemispheric asymmetry of iron already in healthy individuals with a higher concentration of iron in the mid brain of the left hemisphere.

Significant asymmetry was observed in the fractional anisotropy and apparent diffusion coefficient at the rostral SN of PD subjects and significant correlation was rated with UPDRS (Prakash et al. 2012). The right SN had increased fractional anisotropy compared to the left one (Lenfeldt et al. 2015). Proton MRI spectroscopy for monitoring pathologic changes in SN and globus pallidus in early PD showed that the changes in the globus pallidus are more pronounced on the side affected at the onset of PD, which may contribute to the development of asymmetric symptoms and signs; the N-acetyl aspartate (NAA)-to-creatine ratio for the initially symptomatic side of the SN was negatively correlated with the (UPDRS) score (r = − 0.279; p = 0.039) (Wu et al. 2016). Another protein MR spectroscopy study of SN metabolites in PD revealed significant differences in NAA/Creatine, NAA/Cholin, NAA/(Cholin + Creatin) between the ipsi- and the contralateral SN of affected extremity (p < 0.05), indicating metabolic differences (Zhou et al. 2014). A longitudinal high-field (1) H-MR spectroscopy imaging study of the NAA to creatine ratio showed a higher side-to-side asymmetry in the PD group (16.7%) vs. healthy controls (1.6%, p = 0.0024) (Seraji-Bozorgzad et al. 2015).

Levodopa has been shown to provide additional DAergic input, improving movements for the more severely affected side; This suggests that the impact of reduced DA in the cortico-striatal system and the action of DA is not symmetrical (Martinu et al. 2014; Androulidakis et al. 2007)

Cortical degeneration in PD differs between cerebral hemispheres and recent T1-weighted brain MRI findings suggest a pattern of early left and late right hemispheral cortical atrophy in left frontal regions, especially left insula and OB, suggesting early susceptibility of the left hemisphere. This pattern was not influenced by the degree of motor symptom asymmetry (Claassen et al. 2016). Side of onset may influence the pattern of cerebral atrophy in PD. Indeed, left-sided onset PD has a grey matter atrophy in the insula, putamen, anterior cingulate, fronto-temporal cortex and right caudate, while the right side onset PD group showed atrophy at the anterior cingulate, insula, fronto-temporal and occipital cortex (Santos et al. 2016). However, a recent meta-analysis comprising 159 voxel-based morphometry publications (4469 patients, 4307 controls), in contrast to increased left-hemisphere vulnerability in aging and neurodegeneration, showed no consistent pattern in PD (Minkova et al. 2017). Recent magnetoencephalographic studies showed a direct relationship between symptom asymmetry and the laterality of neuronal activity during movement in PD patients, suggesting that left-dominant patients have a different oscillatory pattern than right-dominant patients (Heinrichs-Graham et al. 2017). In agreement with PET-studies reported above, echogenicity as measured with transcranial ultrasound was significantly increased contralateral to the side with more severe symptoms (Berg et al. 2001)

Environmental toxins and laterality in PD

As described in detail (Riederer and Sian-Hülsmann 2012), the vast majority of environmental toxins cause bilateral parkinsonism when applied systematically. This holds true for viral infections, which lesion the SN (Jung et al. 2007) or precipitate parkinsonism after intra-uterine exposure to the influenza virus (Mattock et al. 1988). Studies on post-encephalitic parkinsonism also provide no evidence for unilateral onset of the disease (Espay and Henderson 2011; Dale et al. 2004; Picard et al. 1996). Furthermore, patients with HIV infection, respective AIDS, often exhibit symmetric parkinsonian motor features.

Sporadic parkinsonism can be triggered by chemicals, like those inhibiting the respiratory chain activity, carbon monoxide and various metals. In all these cases, parkinsonism is symmetrical with rare exceptions (Bortolozzi et al. 2003; Rissanen et al. 2010; Riederer and Sian-Hülsmann 2012).

Lateralisation and animal models in Parkinson’s disease

Neurotoxins such as 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are used in animal models for studying pathogenesis and therapeutic strategies in PD. A limitation of neurotoxic models is the unwanted side effect of a toxin (Casey 1997).

As described in detail (Riederer and Sian-Hülsmann 2012; Zheng and Poon 2017), environmental toxins in both animals and humans cause bilateral parkinsonism with some rare exceptions. Therefore, unilaterality especially in the early phase of PD is of particular interest for studies into its pathological basis. For example, asymmetric degeneration of the nigro-striatal dopaminergic pathway results in functional asynchrony between the intact and the 6-OHDA-lesioned caudate-putamen (Monnot et al. 2017).

Therefore, a commonly used animal model employs unilateral injection of 6-OHDA into the SN of rodents. This results in the selective destruction of DAergic neurons, resulting in asymmetric motor deficit similar to that in PD. The side of motor symptoms is contralateral to the side of 6-OHDA injection. Interestingly, the area (SN or striatum or medial forebrain bundles) into which the 6-OHDA is injected determines or predicts the degree of neuronal destruction and thus motor features. Boix et al. (2015) found that partial lesions induced by 6-OHDA injection into the medial forebrain of mice, produced a significant nigrostriatal lesion and behavioral asymmetry. The motor lateralisation can be effectively gauged using the corridor test (Grealish et al. 2010). Recent stereological quantitative analysis of TH-positive dopamine neuron numbers in a rat 6-OHDA nigral lesion model of PD established the relationship between behavioral asymmetry and dopamine neuron loss in the lesioned side (Fabricius et al. 2017). No significant differences were demonstrated in the absolute MRI values between 6-OHDA animals and controls; however, 6-OHDA animals showed significant striatal asymmetry for all MRI parameters in contrast to controls. These PD-related asymmetry ratios might be the result of counteracting changes in both intact and affected striatum and allowed to diagnose PD lesions. As lateralisation is known to occur also in PD patients and might be expected in transgenic PD models as well, MR-derived asymmetry ratios in the striatum might be a useful tool for in vivo phenotyping of animal models of PD (Van Camp et al. 2010). In unilateral 6-OHDA rats treated with a single intraperitoneal injection of l-dopa, asymmetric degeneration of the nigrostriatal dopamine pathway may result in functional asynchrony between the intact and lesioned caudate-putamen and increased interhemispheric synchrony between sensorimotor cortices (Monnot et al. 2017).

Mice were unilaterally infused with either vehicle or rotenone (2 μg/site) in both the medial forebrain bundle and the SN. The forelimb asymmetry (cylinder) test indicated a significant decrease in use of the contralateral forelimb in lesioned animals as compared to the sham group. Densitometric analysis revealed a significant depletion of TH immunofluorescence within the ipsilateral striatum and substantia nigra of lesioned animals. Moreover, a significant bilateral increase in α-syn immunofluorescence was found in the SN of lesioned mice, as compared to control animals (Carriere et al. 2017). As such, the notion is of interest; that systemic gastrointestinal application of rotenone in mice caused bilateral parkinsonism (Pan-Montojo et al. 2010).

Chronic MPTP administration in monkeys results in the progressive degeneration of the nigral neurons thus mirroring a major pathology of PD. The motor disturbances are exhibited contralateral to the unilateral MPTP induced lesion (Schneider et al. 1982), thus supporting the notion that asymmetric lesions in the basal ganglia produce motor lateralisation demonstrated in PD. Perhaps, as the disease progresses the lesions spread to the other unaffected hemisphere and thus losing the motor laterality.

Genetics and lateralisation in PD

As lateralisation of brain structures and motor behaviour has been already described in human foetuses as early as 10 weeks after gestation, with right-handedness observed in 85%, similar to the adult rate of right-handedness, this clearly indicates the presence of asymmetric genetic developmental programmes (Hepper et al. 1998). As the basis for this neuropsychological lateralisation a differential expression and activity of genes and their respective proteins is predicted that modulate signalling properties of the neuronal network including neurotransmission and synaptogenesis (Francks 2011; Margeta and Shen 2010). Indeed, in vertebrate animal models like fish and birds, a clear developmental lateralization programme for body structures has been shown; however, in humans the situation seems to be more complex with independent visceral and brain lateralisation (Tanaka et al. 1999).

Yet, there are only a small number of studies that investigated differential gene expression of brain regions with respect to lateralised gene expression and most of them are hampered by a small sample size of fetal and adult tissues available for analyses related to developmental programmes (Francks 2015). Most of these studies did not reveal any significant difference between left- and right-hemispheric gene expression based on the limited statistical power, however, stringent and region-specific re-analysis of one larger study revealed the first evidence for lateralisation of the expression of a specific set of genes related to synaptic transmission and nervous system development (Karlebach and Francks 2015). How genes identified in the pathogenesis of PD relate to these pathways still needs to be determined, however, mutations in the Parkin gene apparently can be related to strongly lateralised extrapyramidal syndromes (Pramstaller et al. 2002).

Over the last 20 years an increasing number of monogenic forms of PD have been described based on mutations in genes responsible for rare familial forms of the disease (Lill 2016). Most of them account for typical forms of PD that are clinically indistinguishable from the sporadic idiopathic form of the disease and indeed variants in the same genes causing familial PD have been subsequently identified as risk factors for sporadic PD cases (Nalls et al. 2014; Schiesling et al. 2008). The monogenic forms of PD thus present with a similar unilateral onset and develop bilaterally with maintained asymmetry over the course of the disease (Krüger et al. 2001; Lohmann et al. 2003a, b; Zimprich et al. 2004). This asymmetry was further confirmed by functional brain imaging studies in affected mutation carriers using PET and SPECT analyses that showed reduced tracer uptake in the striatum contralateral to the clinically most affected side (Adams et al. 2005; Krüger et al. 2001). This was even observed in asymptomatic LRRK2 mutation carriers, where it was shown that a higher decline of tracer uptake with a marked asymmetry was observed compared to controls at this presymptomatic stage of PD (Nandhagopal et al. 2008). A recent study of 18 asymptomatic LRRK2 mutation carriers showed functional connectivity reductions between the caudal motor part of the left striatum and the ipsilateral superior parietal lobe and increased connectivity between the right SN and bilateral occipital cortical regions, supporting the concept that altered brain connectivity precedes the onset of motor features in a genetic form of PD (Vilas et al. 2016).

Also, for Parkin mutation carriers, which develop an autosomal-recessively inherited juvenile form of PD, a clinical asymmetry correlated with an asymmetric tracer uptake in functional imaging (Hilker et al. 2001). Intriguingly, also heterozygous carriers of Parkin mutations, which are currently discussed to be at risk to develop the typical late onset form of PD, already displayed a presynaptic DAergic dysfunction as illustrated by functional brain imaging (Hilker et al. 2001).

As already mentioned before, Parkin mutation carriers can present with a specific, highly lateralised and therefore unilateral form of parkinsonism that has been described as hemiparkinsonism-hemiatrophy syndrome. This patient, a compound heterozygous carrier of Parkin mutations, presented not only with unilateral parkinsonism but also with an ipsilateral hemiatrophy of the body (Pramstaller et al. 2002). Interestingly, the asymmetry in clinical presentation was not corresponding to the functional brain imaging via PET, as tracer binding was reduced symmetrically. This dissociation between clinical asymmetry and metabolic markers from brain imaging was different to other cases with hemiparkinsonism-hemiatrophy syndrome but consistently observed in other forms of parkinsonism, e.g., dopa-responsive dystonia. Typically the hemiatrophy in these syndromes is thought to be caused by the typical early presentation of unilateral parkinsonism (mean age at onset 43.7 years with the youngest case described at the age of 15 years) leading to reduced motor activity and resulting atrophy (Dziadkiewicz et al. 2013). However, in this case the hemiatrophy observed was independent from the dopaminergic deficit related to the parkinsonian syndrome and may represent an additional factor leading to the asymmetric clinical presentation of parkinsonism in that patient. As the hemiparkinsonism-hemiatrophy syndrome is rare and many of the cases have been described before the era of genetic diagnostics in PD, the contribution of Parkin mutations beyond the single case described remains unclear. However the early disease onset and the typical association of dystonic features closely resemble phenotypes of Parkin-related cases of juvenile PD (Dziadkiewicz et al. 2013).

Beyond mutations in genes responsible for monogenic forms of PD, there is an increasing number of genetic risk factors ranging from rare variants with substantial effects to common variants with small effects that contribute to the complex genetic architecture of PD (Manolio et al. 2009; Larsen et al. 2018). These forms typically present as sporadic PD and therefore, based on the clinical presentation, no specific features in terms of lateralisation can be expected.

Are there clinical consequences of asymmetry in PD?

It is a fact, that onset of PD in most cases shows asymmetrical pathology of the nigrostriatal DA system. Therefore, it has been assumed that right/left unilateral onset causes variation in loop(s) (dys)function(s) (Leh et al. 2010). If so, it is not farfetched to assume clinical and drug-induced consequences and differences caused by right- or left-onset.

Hypothetically, unilateral onset of PD may contribute to (1) variations of symptom onset, severity of disease, progression rate and prognosis. (2) The compensatory capacity of both hemispheres may well be different and this might influence disease pathology and progression. (3) Provokes right-sided early onset degeneration earlier and more severe onset of depression, anxiety and less creativity? And is there a better prognosis - milder progression - in this type of early right-sided PD pathology? (4) Is early left-sided degenerative onset accompanied by early cognitive problems/dysfunctions, leading to earlier dementive symptomology and poorer prognosis? (5) Are there consequences to be considered with regard to clinical studies evaluating drug efficacy, side effect/adverse reaction profiling? Do we lose information for disease modifying/neuroprotective results if right-onset and left-onset PD patients are tested together and clinical endpoints are not differentiated in these groups? (6) Could non-pharmacological interventions in a unilateral setting-enriched therapy improve both progression and pharmacotherapeutic response?

Because of the assumed importance of asymmetrical processes in early PD we emphasise to enrol not only the basic principles of laterality in PD but also its consequences for disease progression, prognosis and therapeutic strategies in clinical studies designed to test these open questions.

Is there a therapy related to asymmetric drug response?

As evidence suggests an asymmetry of the DAT population and a greater number of D1- and D2-DA receptors in the right striatum this might ascribe for a poor prognosis of left-sided onset PD (Riederer and Sian-Hülsmann 2012). Greater motor improvement was seen in right hemibody PD patients after DAergic therapy (Foster et al. 2009). l-DOPA therapy shows the greatest benefit in motor symptoms on the more affected side. Indeed more recent clinical studies in right-handed PD patients using fMRI to investigate asymmetrical effects of levodopa on the hemodynamic correlates of finger movements showed that levodopa led to larger differences in cerebral activity for movements of the more affected left side. These results of Martinu et al. (2014) suggest an impact of reduced DA in the cortico-striatal system and the action of levodopa is not symmetrical (Martinu et al. 2014). This corresponds to the reports about beneficial effects in patients with unilateral deep-brain stimulation (DBS) of the subthalamic nucleus (STN) (Hershey et al. 2008; Riederer and Sian-Hülsmann 2012).

Improvement as recorded with the UPDRS after unilateral DBS in the more affected side was greater in the contralateral side, while spatial delayed response was more impaired.

In most patients levodopa induced dyskinesias are first exhibited in the more affected side (Colosimo et al. 2010).

Dopamine receptor agonists and levodopa promote motor lateralisation in PD (Androulidakis et al. 2007). Even as such little evidence suggests variation of both pharmacotherapeutic strategies and DBS in right/left-onset PD this also might hold true for appearance and severity of side effects and adverse reactions. If such a working hypothesis holds true, the outcome of clinical studies especially for clinical trials designed to prove neuroprotection and disease modification may be at variance in right/left-onset PD patients (Riederer and Sian-Hülsmann 2012). Also unilateral stimulation via non-pharmacological so-called “enriched therapies” may be suitable to avoid (reduce) neurodegenerative processes in early-onset right or left-onset PD (Riederer and Sian-Hülsmann 2012)


It appears that in the early stages of idiopathic PD there is asymmetric neurodegeneration, which perhaps corresponds to the characteristic unilateral manifestation of motor dysfunction. The neuronal cell loss is contralateral to the side of motor symptom onset. Subsequently, as the disease progresses, bilateral motor symptoms are exhibited, probably relating to a more widespread cell destruction in the two hemispheres. However, the appendicular motor asymmetry often persists.

Lateralisation of motor symptoms and neurodegeneration has two important implications. Firstly, the side of symptom onset (left or right side) may have vital implications about the prognosis of the illness and the rate of disease progression. Secondly, asymmetry of motor dysfunction should be carefully considered for the treatment plan. Indeed, deep brain stimulation in the more affected hemisphere has proved to be more beneficial to appendicular motor symptoms.

Also the right/left side dominant motor symptoms may ascribe for the presence of subgroups in PD. Clearly, this leads to new avenues of exploration in the quest of the pathogenesis of PD.

From this review, it is clear and of utmost interest to perform more clinical, neuropathological and experimental studies to clarify the basis of asymmetry in PD.



The work of RK, GH and PK was supported by grants from the Luxembourg National Research Fund (FNR) within the National Centre of Excellence in Research on Parkinson’s disease (NCER-PD), the PEARL programme (FNR; FNR/P13/6682797 to RK) and by the European Union’s Horizon2020 research and innovation program under grant agreement No. 692320 (CENTRE-PD to RK).


  1. Adams JR, van Netten H, Schulzer M, Mak E, Mckenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M, Gasser T, Uitti RJ, Calne DB, Wszolek ZK, Stoessl AJ (2005) PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain 128(12):2777–2785 PubMedCrossRefGoogle Scholar
  2. Amick MM, Grace J, Chou KL (2006) Body side of motor symptom onset in Parkinson’s disease is associated with memory performance. J Int Neuropsychol Soc 12(5):736–740PubMedCrossRefGoogle Scholar
  3. Amtage F, Hellwig S, Kreft A, Spehl T, Glauche V, Winkler C, Rijntjes M, Hellwig B, Weiller C, Weber WA, Tüscher O, Meyer PT (2014) Neuronal correlates of clinical asymmetry in progressive supranuclear palsy. Clin Nucl Med 39:319–325PubMedCrossRefGoogle Scholar
  4. Androulidakis AG, Kühn AA, Chen CC, Blomstedt P, Kempf F, Kupsch A, Schneider GH, Doyle L, Dowsey-Limousin P, Hariz MI, Brown P (2007) Dopaminergic therapy promotes lateralized motor activity in the subthalamic area in Parkinson’s disease. Brain 130(Pt 2):457–468PubMedCrossRefGoogle Scholar
  5. Attems J, Walker L, Jellinger KA (2014) Olfactory bulb involvement in neurodegenerative diseases. Acta Neuropathol 127:459–475PubMedCrossRefGoogle Scholar
  6. Azuma M, Hirai T, Yamada K, Yamashita S, Ando Y, Tateishi M, Iryo Y, Yoneda T, Kitajima M, Wang Y, Yamashita Y (2016) Lateral asymmetry and spatial difference of iron deposition in the substantia nigra of patients with Parkinson disease measured with quantitative susceptibility mapping. AJNR Am J Neuroradiol 37:782–788PubMedPubMedCentralCrossRefGoogle Scholar
  7. Barolin GS, Bernheimer H, Hornykiewicz O (1964) Seitenverschiedenes Verhalten des Dopamins (3-HyHydroxytyramin) im Gehirn eines Falles von Hemiparkinsonismus. Schweizer Archiv für Neurologie undPsychiatrie 94:241Google Scholar
  8. Barrett MJ, Wylie SA, Harrison MB, Wooten GF (2011) Handedness and motor symptom asymmetry in Parkinson’s disease. J Neurol Neurosurg Psychiatry 82:1122–1124PubMedCrossRefGoogle Scholar
  9. Batla A, Stamelou M, Mensikova K, Kaiserova M, Tuckova L, Kanovsky P, Quinn N, Bhatia KP (2013) Markedly asymmetric presentation in multiple system atrophy. Parkinsonism Relat Disord 19:901–905PubMedCrossRefGoogle Scholar
  10. Baumann CR, Held U, Valko PO, Wienecke M, Waldvogel D (2014) Body side and predominant motor features at the onset of Parkinson’s disease are linked to motor and nonmotor progression. Mov Disord 29:207–213PubMedCrossRefGoogle Scholar
  11. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG, Arizona Parkinson’s Disease Consortium (2010) Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119:689–702PubMedPubMedCentralCrossRefGoogle Scholar
  12. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG (2000) Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 15:692–698PubMedCrossRefGoogle Scholar
  13. Beretta VS, Gobbi LT, Lirani-Silva E, Simieli L, Orcioli-Silva D, Barbieri FA (2015) Challenging postural tasks increase asymmetry in patients with Parkinson’s disease. PLoS One 10:e0137722PubMedPubMedCentralCrossRefGoogle Scholar
  14. Berg D, Siefker C, Becker G (2001) Echogenicity of the substantia nigra in Parkinson’s disease and its relation to clinical findings. J Neurol 248(8):684–689PubMedCrossRefGoogle Scholar
  15. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415–455PubMedCrossRefGoogle Scholar
  16. Bogdanova Y, Cronin-Golomb A (2012) Neurocognitive correlates of apathy and anxiety in Parkinson’s disease. Parkinsons Dis 2012:793076PubMedGoogle Scholar
  17. Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, Frey KA (2006) Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006 Sep 26(9):1198–1212PubMedCrossRefGoogle Scholar
  18. Boix J, Padel T, Paul G (2015) A partial lesion model of Parkinson’s disease in mice—characterization of a 6-OHDA-induced medial forebrain bundle lesion. Behav Brain Res 1(284):196–206CrossRefGoogle Scholar
  19. Bortolozzi A, Duffard R, de Duffard AM (2003) Asymmetrical development of the monoamine systems in 2,4-dichlorophenoxyacetic acid treated rats. Neurotoxicology 24(1):149–157PubMedCrossRefGoogle Scholar
  20. Braak H, Del Tredici K (2008) Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 70:1916–1925PubMedCrossRefGoogle Scholar
  21. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRefGoogle Scholar
  22. Brichta L, Greengard P (2014) Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update. Front Neuroanat 8:152PubMedPubMedCentralCrossRefGoogle Scholar
  23. Brooks DJ, Pavese N (2009) Recent imaging advances in the diagnosis and management of Parkinson’s disease. Med Rep 1:82Google Scholar
  24. Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, Santos DP, Blanz J, Obermaier CD, Strojny C, Savas JN, Kiskinis E, Zhuang X, Krüger R, Surmeier DJ, Krainc D (2017) Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science 22(357(6357)):1255–1261CrossRefGoogle Scholar
  25. Caligiuri ME, Nisticò R, Arabia G, Morelli M, Novellino F, Salsone M, Barbagallo G, Lupo A, Cascini GL, Galea D, Cherubini A, Quattrone A (2016) Alterations of putaminal shape in de novo Parkinson’s disease. Mov Disord 31:676–683PubMedCrossRefGoogle Scholar
  26. Carriere CH, Kang NH, Niles LP (2017) Bilateral upregulation of alpha-synuclein expression in the mouse substantia nigra by intracranial rotenone treatment. Exp Toxicol Pathol 69:109–114PubMedCrossRefGoogle Scholar
  27. Casey DE (1997) The relationship of pharmacology to side effects. J Clin Psychiatry 58(Suppl 10):55–62PubMedGoogle Scholar
  28. Cheesman AL, Barker RA, Lewis SJ, Robbins TW, Owen AM, Brooks DJ (2005) Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson’s disease. J Neurol Neurosurg Psychiatry 76:1204–1210PubMedPubMedCentralCrossRefGoogle Scholar
  29. Claassen DO, McDonell KE, Donahue M, Rawal S, Wylie SA, Neimat JS, Kang H, Hedera P, Zald D, Landman B, Dawant B, Rane S (2016) Cortical asymmetry in Parkinson’s disease: early susceptibility of the left hemisphere. Brain Behav 6:1–10 e00573CrossRefGoogle Scholar
  30. Colloby SJ, McParland S, O'Brien JT, Attems J (2012) Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain 135:2798–2808PubMedCrossRefGoogle Scholar
  31. Colosimo C, Martínez-Martín P, Fabbrini G, Hauser RA, Merello M, Miyasaki J, Poewe W, Sampaio C, Rascol O, Stebbins GT, Schrag A, Goetz CG (2010) Task force report on scales to assess dyskinesia in Parkinson’s disease: critique and recommendations. Mov Disord 15(25(9)):1131–1142CrossRefGoogle Scholar
  32. Counihan TJ, Penney JB Jr (1998) Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson’s disease brains. J Neurol Neurosurg Psychiatry 65:164–169PubMedPubMedCentralCrossRefGoogle Scholar
  33. Cubo E, Martín PM, Martin-Gonzalez JA, Rodríguez-Blázquez C, Kulisevsky J, ELEP Group Members (2010) Motor laterality asymmetry and nonmotor symptoms in Parkinson’s disease. Mov Disord 25:70–75PubMedCrossRefGoogle Scholar
  34. Dale RC, Church AJ, Surtees RA, Lees AJ, Adcock JE, Harding B, Neville BG, Giovannoni G (2004) Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain 127:21–33PubMedCrossRefGoogle Scholar
  35. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 122(Pt 8):1437–1448PubMedCrossRefGoogle Scholar
  36. de la Fuente-Fernández R, Kishore A, Calne DB, Ruth TJ, Stoessl AJ (2000) Nigrostriatal dopamine system and motor lateralization. Behav Brain Res 112:63–68PubMedCrossRefGoogle Scholar
  37. Dethy S, Van Blercom N, Damhaut P, Wikler D, Hildebrand J, Goldman S (1998) Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in parkinsonism. Mov Disord 13:275–280PubMedCrossRefGoogle Scholar
  38. Dijkstra AA, Voorn P, Berendse HW, Groenewegen HJ, Netherlands Brain Bank, Rozemuller AJ, van de Berg WD (2014) Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson’s disease. Mov Disord 29:1244–1251PubMedCrossRefGoogle Scholar
  39. Direnfeld LK, Albert ML, Volicer L, Langlais PJ, Marquis J, Kaplan E (1984) Parkinson’s disease. The possible relationship of laterality to dementia and neurochemical findings. Arch Neurol 41:935–941PubMedCrossRefGoogle Scholar
  40. Djaldetti R, Ziv I, Melamed E (2006) The mystery of motor asymmetry in Parkinson’s disease. Lancet Neurol 5:796–802PubMedCrossRefGoogle Scholar
  41. Djaldetti R, Lorberboym M, Karmon Y, Treves TA, Ziv I, Melamed E (2011) Residual striatal dopaminergic nerve terminals in very long-standing Parkinson's disease: a single photon emission computed tomography imaging study. Mov Disord 26:327–330PubMedCrossRefGoogle Scholar
  42. Doherty KM, Silveira-Moriyama L, Parkkinen L, Healy DG, Farrell M, Mencacci NE, Ahmed Z, Brett FM, Hardy J, Quinn N, Counihan TJ, Lynch T, Fox ZV, Revesz T, Lees AJ, Holton JL (2013) Parkin disease: a clinicopathologic entity? JAMA Neurol 70:571–579PubMedPubMedCentralCrossRefGoogle Scholar
  43. Donadio V, Incensi A, Rizzo G, Scaglione C, Capellari S, Fileccia E, Avoni P, Liguori R (2017) Spine topographical distribution of skin α-synuclein deposits in idiopathic Parkinson disease. J Neuropathol Exp Neurol 76(5):384–389PubMedCrossRefGoogle Scholar
  44. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI (1992) Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 55:138–142PubMedPubMedCentralCrossRefGoogle Scholar
  45. Durmaz NF, Yorubulut M, Akbostanci CM (2016) May substantia nigra volume asymmetry be an indicator of motor asymmetry in Parkinson’s disease? A retrospective analysis (abstract). Mov Disord 31(suppl 2):1204Google Scholar
  46. Dziadkiewicz A, Białecka M, Janik P, Sławek J (2013) Hemiparkinsonism-hemiatrophy syndrome—report on two cases and review of the literature. Neurol Neurochir Pol 47(4):387–392 PubMedGoogle Scholar
  47. Erro R, Barone P, Vicidomini C, Picillo M, Pappatà S (2013) Patients with Parkinson’s disease and scans with (predominant) ipsilateral dopaminergic deficit. J Neurol 260:2405–2406PubMedCrossRefGoogle Scholar
  48. Erro R, Spina E, Barone P, Pellecchia MT (2015) On the relationship between side of onset and cognition in Parkinson disease. Parkinsonism Relat Disord 21:1391–1392PubMedCrossRefGoogle Scholar
  49. Espay AJ, Henderson KK (2011) Postencephalitic parkinsonism and basal ganglia necrosis due to Epstein-Barr virus infection. Neurology 26(76(17)):1529–1530CrossRefGoogle Scholar
  50. Fabricius K, Barkholt P, Jelsing J, Hansen HH (2017) Application of the physical disector principle for quantification of dopaminergic neuronal loss in a rat 6-hydroxydopamine nigral lesion model of Parkinson’s disease. Front Neuroanat 11:109PubMedPubMedCentralCrossRefGoogle Scholar
  51. Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283–2301PubMedCrossRefGoogle Scholar
  52. Foster ER, Black KJ, Antenor-Dorsey JA, Perlmutter JS, Hershey T (2008) Motor asymmetry and substantia nigra volume are related to spatial delayed response performance in Parkinson disease. Brain Cogn 67:1–10PubMedCrossRefGoogle Scholar
  53. Foster PS, Drago V, Skidmore F, Skoblar BM, Crucian GP, Heilman KM (2009) Greater motor improvement in right hemibody Parkinson’s patients after dopaminergic medications. Parkinsonism Relat Disord 15:20–23PubMedCrossRefGoogle Scholar
  54. Francks C (2011) Leucine-rich repeat genes and the fine-tuning of synapses. Biol Psychiatry 69(9):820–821. PubMedCrossRefGoogle Scholar
  55. Francks C (2015) Exploring human brain lateralization with molecular genetics and genomics. Ann N Y Acad Sci 1359(1):1–13. PubMedCrossRefGoogle Scholar
  56. Frazzitta G, Pezzoli G, Bertotti G, Maestri R (2013) Asymmetry and freezing of gait in parkinsonian patients. J Neurol 260:71–76PubMedCrossRefGoogle Scholar
  57. German DC, Manaye K, Smith WK, Woodward DJ, Saper CB (1989) Midbrain dopaminergic cell loss in Parkinson’s disease: computer visualization. Ann Neurol 26:507–514PubMedCrossRefGoogle Scholar
  58. Glick SD, Ross DA, Hough LB (1982) Lateral asymmetry of neurotransmitters in human brain. Brain Res 234:53–63PubMedCrossRefGoogle Scholar
  59. Gómez-Esteban JC, Tijero B, Ciordia R, Berganzo K, Somme J, Lezcano E, Zarranz JJ (2010) Factors influencing the symmetry of Parkinson’s disease symptoms. Clin Neurol Neurosurg 112:302–305PubMedCrossRefGoogle Scholar
  60. Gomperts SN, Locascio JJ et al (2016) Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol 73:1334–1341PubMedPubMedCentralCrossRefGoogle Scholar
  61. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA (1995) Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease. Neurology 45:1138–1143PubMedCrossRefGoogle Scholar
  62. Grealish S, Mattsson B, Draxler P, Björklund A (2010) Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson’s disease. Eur J Neurosci 31(12):2266–2278PubMedCrossRefGoogle Scholar
  63. Halliday G, Murphy K (2010) Pathology of Parkinson’s disease—an overview. In: AHV S, AET L et al (eds) Movement disorders, vol 4. Saunders-Elsevier, pp 132–154Google Scholar
  64. Ham JH, Lee JJ, Kim JS, Lee PH, Sohn YH (2015) Is dominant-side onset associated with a better motor compensation in Parkinson’s disease? Mov Disord 30:1921–1925PubMedCrossRefGoogle Scholar
  65. Hanna-Pladdy B, Pahwa R, Lyons KE (2015) Paradoxical effect of dopamine medication on cognition in Parkinson’s disease: relationship to side of motor onset. J Int Neuropsychol Soc 21(4):259–270PubMedPubMedCentralCrossRefGoogle Scholar
  66. Hansen AK, Knudsen K, Lillethorup TP, Landau AM, Parbo P, Fedorova T, Audrain H, Bender D, Østergaard K, Brooks DJ, Borghammer P (2016) In vivo imaging of neuromelanin in Parkinson’s disease using 18F-AV-1451 PET. Brain 139:2039–2049PubMedCrossRefGoogle Scholar
  67. Hassler R (1938) Zur Pathologie der Paralysis agitains und des postenzephalitischen Parkinsonismus. J Psychol Neurol 48:387–476Google Scholar
  68. Heckmann JG, Höcherl C, Lang C, Platsch G, Hummel T (2004) Hemihyposmia in a case of hemiparkinsonism. Eur J Gen Med 1:72–73CrossRefGoogle Scholar
  69. Heinrichs-Graham E, Santamaria PM, Gendelman HE, Wilson TW (2017) The cortical signature of symptom laterality in Parkinson’s disease. Neuroimage Clin 14:433–440PubMedPubMedCentralCrossRefGoogle Scholar
  70. Hepper PG, McCartney GR, Shannon EA (1998) Lateralised behaviour in first trimester human foetuses. Neuropsychologia 36(6):531–534. PubMedCrossRefGoogle Scholar
  71. Hershey T, Wu J, Weaver PM, Perantie DC, Karimi M, Tabbal SD, Perlmutter JS (2008) Unilateral vs. bilateral STN DBS effects on working memory and motor function in Parkinson disease. Exp Neurol 210(2):402–408PubMedCrossRefGoogle Scholar
  72. Hilker R, Klein C, Ghaemi M, Kis B, Strotmann T, Ozelius LJ, Lenz O, Vieregge P, Herholz K, Heiss WD, Pramstaller PP (2001) Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 49(3):367–376. PubMedCrossRefGoogle Scholar
  73. Hipp G (2015) Das Luxemburger Parkinson-Kohortenprogramm: Neue Strategien für eine umfassende Studie zur Erfassung von Biodaten und klinischen Daten. Basal ganglia [internet]. Elsevier 5(1):XVIGoogle Scholar
  74. Hobson DE (2012) Asymmetry in parkinsonism, spreading pathogens and the nose. Parkinsonism Relat Disord 18(1):1–9PubMedCrossRefGoogle Scholar
  75. Hoshiyama E, Kadowaki T et al (2015) The decreasing of dopamine-transporter uptake on the right ipsilateral side of tremor in a patient with Parkinson’s disease [abstract]. Mov Disord 30(Suppl 1):996Google Scholar
  76. Houlden H, Singleton AB (2012) The genetics and neuropathology of Parkinson’s disease. Acta Neuropathol 124:325–338PubMedPubMedCentralCrossRefGoogle Scholar
  77. Huang P, Tan YY, Liu DQ, Herzallah MM, Lapidow E, Wang Y, Zang YF, Gluck MA, Chen SD (2017) Motor-symptom laterality affects acquisition in Parkinson’s disease: a cognitive and functional magnetic resonance imaging study. Mov Disord 32:1047–1055PubMedCrossRefGoogle Scholar
  78. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedPubMedCentralCrossRefGoogle Scholar
  79. Hwang I, Sohn CH, Kang KM, Jeon BS, Kim HJ, Choi SH, Yun TJ, Kim JH (2015) Differentiation of parkinsonism-predominant multiple system atrophy from idiopathic Parkinson disease using 3T susceptibility-weighted MR imaging, focusing on putaminal change and lesion asymmetry. AJNR Am J Neuroradiol 36:2227–2234PubMedCrossRefGoogle Scholar
  80. Jellinger KA (2012) Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord 27:8–30PubMedCrossRefGoogle Scholar
  81. Jellinger KA (2014) Neuropathology of Parkinson’s disease. In: Thomas M (ed) Inflammation in Parkinson’s disease: scientific and clinical aspects. Springer International Publishing, Switzerland, pp 25–74Google Scholar
  82. Jung KY, Chung CS, Park KW (2007) Bilateral medial temporal lesions in Japanese encephalitis. Neurology 17(68(16)):1319CrossRefGoogle Scholar
  83. Kaasinen V (2015) Ipsilateral deficits of dopaminergic neurotransmission in Parkinson’s disease. Ann Clin Transl Neurol 3:21–26PubMedPubMedCentralCrossRefGoogle Scholar
  84. Karlebach G, Francks C (2015) Lateralization of gene expression in human language cortex. Cortex 67:30–36. PubMedCrossRefGoogle Scholar
  85. Kempster PA, Gibb WR, Stern GM, Lees AJ (1989) Asymmetry of substantia nigra neuronal loss in Parkinson’s disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry 52:72–76PubMedPubMedCentralCrossRefGoogle Scholar
  86. Kiely AP, Ling H, Asi YT, Kara E, Proukakis C, Schapira AH, Morris HR, Roberts HC, Lubbe S, Limousin P, Lewis PA, Lees AJ, Quinn N, Hardy J, Love S, Revesz T, Houlden H, Holton JL (2015) Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Mol Neurodegener 10:41PubMedPubMedCentralCrossRefGoogle Scholar
  87. Kim JS, Yang JJ, Lee JM, Youn J, Kim JM, Cho JW4 (2014) Topographic pattern of cortical thinning with consideration of motor laterality in Parkinson disease. Parkinsonism Relat Disord 20:1186–1190PubMedCrossRefGoogle Scholar
  88. Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med 318:876–880PubMedCrossRefGoogle Scholar
  89. Klawans HL Jr (1972) Relationship between handedness and side of onset of parkinsonism. Lancet 15(1(7755)):850CrossRefGoogle Scholar
  90. Knudsen GM, Karlsborg M, Thomsen G, Krabbe K, Regeur L, Nygaard T, Videbaek C, Werdelin L (2004) Imaging of dopamine transporters and D2 receptors in patients with Parkinson’s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 31:1631–1638PubMedCrossRefGoogle Scholar
  91. Kojovic M et al (2012) Functional reorganization of sensorimotor cortex in early Parkinson disease. Neurology 78:1441–1448PubMedPubMedCentralCrossRefGoogle Scholar
  92. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 136:2419–2431PubMedPubMedCentralCrossRefGoogle Scholar
  93. Kovacs GG, Milenkovic IJ, Preusser M, Budka H (2008) Nigral burden of alpha-synuclein correlates with striatal dopamine deficit. Mov Disord 23:1608–1612PubMedCrossRefGoogle Scholar
  94. Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W (2014) Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord 29:1767–1773PubMedCrossRefGoogle Scholar
  95. Krüger R, Kuhn W, Leenders KL, Sprengelmeyer R, Müller T, Woitalla D, Portman AT, Maguire RP, Veenma L, Schröder U, Schöls L, Epplen JT, Riess O, Przuntek H (2001) Familial parkinsonism with synuclein pathology: Clinical and PET studies of A30P mutation carriers. Neurology 56(10):1355–1362. PubMedCrossRefGoogle Scholar
  96. Kumakura Y, Gjedde A, Danielsen EH, Christensen S, Cumming P (2006) Dopamine storage capacity in caudate and putamen of patients with early Parkinson’s disease: correlation with asymmetry of motor symptoms. J Cereb Blood Flow Metab 26:358–370PubMedCrossRefGoogle Scholar
  97. Kumar S, Mandal MK (2003) Task-specific motor performance and musculoskeletal response in self-classified right handers. Int J Neurosci 113(11):1487–1495PubMedCrossRefGoogle Scholar
  98. Kumar A, Mann S et al (2003) [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson’s disease. Brain 126:2648–2655PubMedCrossRefGoogle Scholar
  99. Kwon DH, Kim JM, Oh SH, Jeong HJ, Park SY, Oh ES, Chi JG, Kim YB, Jeon BS, Cho ZH (2012) Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 71:267–277PubMedCrossRefGoogle Scholar
  100. Laihinen A, Ruottinen H, Rinne JO, Haaparanta M, Bergman J, Solin O, Koskenvuo M, Marttila R, Rinne UK (2000) Risk for Parkinson’s disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J Neurol 247(Suppl 2):II110–II113PubMedGoogle Scholar
  101. Larsen SB, Hanss Z, Krüger R (2018) The genetic architecture of mitochondrial dysfunction in Parkinson's disease. Cell Tissue Res.
  102. Lee EY, Sen S, Eslinger PJ, Wagner D, Kong L, Lewis MM, Du G, Huang X (2015) Side of motor onset is associated with hemisphere-specific memory decline and lateralized gray matter loss in Parkinson’s disease. Parkinsonism Relat Disord 21:465–470PubMedPubMedCentralCrossRefGoogle Scholar
  103. Lee SH, Cho H, Choi JY, Lee JH, Ryu YH, Lee MS, Lyoo CH (2018) Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases. Mov Disord 33:262–272PubMedCrossRefGoogle Scholar
  104. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD, Frackowiak RS (1990) The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson’s disease. Arch Neurol 47(12):1290–1298PubMedCrossRefGoogle Scholar
  105. Leh SE, Petrides M, Strafella AP (2010) The neural circuitry of executive functions in healthy subjects and Parkinson’s disease. Neuropsychopharmacology. 2010 Jan 35(1):70–85PubMedCrossRefGoogle Scholar
  106. Lehéricy S, Bardinet E, Poupon C, Vidailhet M, François C (2014) 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson’s disease. Mov Disord 29:1574–1581PubMedCrossRefGoogle Scholar
  107. Lenfeldt N, Larsson A, Nyberg L, Birgander R, Forsgren L (2015) Fractional anisotropy in the substantia nigra in Parkinson’s disease: a complex picture. Eur J Neurol 22:1408–1414PubMedCrossRefGoogle Scholar
  108. Li J, Gu CZ, Su JB, Zhu LH, Zhou Y, Huang HY, Liu CF (2016) Changes in olfactory bulb volume in Parkinson’s disease: a systematic review and meta-analysis. PLoS One 22:11(2)Google Scholar
  109. Lill CM (2016) Genetics of Parkinson’s disease. Mol Cell Probes 30(6):386–396. PubMedCrossRefGoogle Scholar
  110. Liu SY, Wu JJ, Zhao J, Huang SF, Wang YX, Ge JJ, Wu P, Zuo CT, Ding ZT, Wang J (2015) Onset-related subtypes of Parkinson’s disease differ in the patterns of striatal dopaminergic dysfunction: a positron emission tomography study. Parkinsonism Relat Disord 21:1448–1453PubMedCrossRefGoogle Scholar
  111. Lizbinski KM, Dacks AM (2018) Intrinsic and extrinsic neuromodulation of olfactory processing. Front Cell Neurosci 9(11):424CrossRefGoogle Scholar
  112. Lohmann E, Periquet M et al (2003a) How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 54:176–185PubMedCrossRefGoogle Scholar
  113. Lohmann E, Periquet M, Bonifati V, Wood NW, De Michele G, Bonnet AM, Fraix V, Broussolle E, Horstink MW, Vidailhet M, Verpillat P, Gasser T, Nicholl D, Teive H, Raskin S, Rascol O, Destée A, Ruberg M, Gasparini F, Meco G, Agid Y, Durr A, Brice A, French Parkinson’s Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson’s Disease (2003b) How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 54(2):176–185. PubMedCrossRefGoogle Scholar
  114. Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE Kantarci K, Boeve BF, Pandey MK, Bruinsma T, Knopman DS, Jones DT, Petrucelli L, Cook CN, Graff-Radford NR, Dickson DW, Petersen RC, Jack CR Jr, Murray ME (2016) An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 4:58PubMedPubMedCentralCrossRefGoogle Scholar
  115. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM (2009) Finding the missing heritability of complex diseases. Nature 461(7265):747–753. PubMedPubMedCentralCrossRefGoogle Scholar
  116. Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Charney DS, van Dyck C, Hoffer PB, Innis RP (1996) [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 46:231–237PubMedCrossRefGoogle Scholar
  117. Margeta MA, Shen K (2010) Molecular mechanisms of synaptic specificity. Mol Cell Neurosci 43(3):261–267. PubMedCrossRefGoogle Scholar
  118. Marinelli L, Piccardo A, Mori L, Morbelli S, Girtler N, Castaldi A, Picco A, Trompetto C, Ghilardi MF, Abbruzzese G, Nobili F (2015) Orbitofrontal (18) F-DOPA uptake and movement preparation in Parkinson’s disease. Parkinsons Dis 2015:180940PubMedPubMedCentralGoogle Scholar
  119. Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML, Vasdev N, Dickerson BC, Gomperts SN, Growdon JH, Johnson KA, Frosch MP, Hyman BT, Gómez-Isla T (2015) Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78:787–800PubMedPubMedCentralCrossRefGoogle Scholar
  120. Martinu K, Nagano-Saito A, Fogel S, Monchi O (2014) Asymmetrical effect of levodopa on the neural activity of motor regions in PD. PLoS One 9:e111600PubMedPubMedCentralCrossRefGoogle Scholar
  121. Mattock C, Marmot M, Stern G (1988) Could Parkinson’s disease follow intra-uterine influenza?: a speculative hypothesis. J Neurol Neurosurg Psychiatry 51(6):753–756PubMedPubMedCentralCrossRefGoogle Scholar
  122. McNeill A, Wu RM, Tzen KY, Aguiar PC, Arbelo JM, Barone P, Bhatia K, Barsottini O, Bonifati V, Bostantjopoulou S, Bressan R, Cossu G, Cortelli P, Felicio A, Ferraz HB, Herrera J, Houlden H, Hoexter M, Isla C, Lees A, Lorenzo-Betancor O, Mencacci NE, Pastor P, Pappata S, Pellecchia MT, Silveria-Moriyama L, Varrone A, Foltynie T, Schapira AH (2013) Dopaminergic neuronal imaging in genetic Parkinson’s disease: insights into pathogenesis. PLoS One 8:e69190PubMedPubMedCentralCrossRefGoogle Scholar
  123. Minkova L, Habich A, Peter J, Kaller CP, Eickhoff SB, Klöppel S (2017) Gray matter asymmetries in aging and neurodegeneration: a review and meta-analysis. Hum Brain Mapp 38:5890–5904PubMedCrossRefGoogle Scholar
  124. Mirabella G, Fragola M, Giannini G, Modugno N, Lakens D (2017) Inhibitory control is not lateralized in Parkinson’s patients. Neuropsychologia 102:177–189PubMedCrossRefGoogle Scholar
  125. Modestino EJ, Amenechi C, Reinhofer A, O'Toole P (2017) Side-of-onset of Parkinson’s disease in relation to neuropsychological measures. Brain Behav 19:7(1)Google Scholar
  126. Moessnang C, Frank G, Bogdahn U, Winkler J, Greenlee MW, Klucken J (2011) Altered activation patterns within the olfactory network in Parkinson’s disease. Cereb Cortex 21:1246–1253PubMedCrossRefGoogle Scholar
  127. Monnot C, Zhang X, Nikkhou-Aski S, Damberg P, Svenningsson P (2017) Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism. Exp Neurol 292:11–20PubMedPubMedCentralCrossRefGoogle Scholar
  128. Munhoz RP, Espay AJ, Morgante F, Li JY, Teive HA, Dunn E, Gallin E, Litvan I (2013) Long-duration Parkinson’s disease: role of lateralization of motor features. Parkinsonism Relat Disord 19:77–80PubMedCrossRefGoogle Scholar
  129. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, International Parkinson's Disease Genomics Consortium (IPDGC), Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Ashkenazi Jewish Dataset Investigator, Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE), North American Brain Expression Consortium (NABEC), United Kingdom Brain Expression Consortium (UKBEC), Greek Parkinson's Disease Consortium, Alzheimer Genetic Analysis Group, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet 46(9):989–993. PubMedPubMedCentralCrossRefGoogle Scholar
  130. Nandhagopal R, Mak E, Schulzer M, McKenzie J, McCormick S, Sossi V, Ruth TJ, Strongosky A, Farrer MJ, Wszolek ZK, Stoessl AJ (2008) Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 71(22):1790–1795. PubMedPubMedCentralCrossRefGoogle Scholar
  131. Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, Lee CS, McKenzie J, McCormick S, Samii A, Troiano A, Ruth TJ, Sossi V, de la Fuente-Fernandez R, Calne DB, Stoessl AJ (2009) Longitudinal progression of sporadic Parkinson’s disease: a multi-tracer positron emission tomography study. Brain 132:2970–2979PubMedCrossRefGoogle Scholar
  132. Nestrasil I, Michaeli S, Liimatainen T, Rydeen CE, Kotz CM, Nixon JP, Hanson T, Tuite PJ (2010) T1rho and T2rho MRI in the evaluation of Parkinson’s disease. J Neurol 257:964–968PubMedPubMedCentralCrossRefGoogle Scholar
  133. Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, Li A, Holton J, Guerreiro R, Paudel R, Segarane B, Singleton A, Lees A, Hardy J, Houlden H, Revesz T, Wood NW (2009) Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 132:1783–1794PubMedPubMedCentralCrossRefGoogle Scholar
  134. Noh Y, Sung YH, Lee J, Kim EY (2015) Nigrosome 1 detection at 3T MRI for the diagnosis of early-stage idiopathic Parkinson disease: assessment of diagnostic accuracy and agreement on imaging asymmetry and clinical laterality. AJNR Am J Neuroradiol 36:2010–2016PubMedCrossRefGoogle Scholar
  135. Pakkenberg B, Møller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H (1991) The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson’s disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 54:30–33PubMedPubMedCentralCrossRefGoogle Scholar
  136. Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, Funk RH (2010) Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 5:e8762PubMedPubMedCentralCrossRefGoogle Scholar
  137. Park JW, Kwon DY, Choi JH, Park MH, Yoon HK (2018) Olfactory dysfunctions in drug-naïve Parkinson’s disease with mild cognitive impairment. Parkinsonism Relat Disord 46:69–73PubMedCrossRefGoogle Scholar
  138. Pellicano C, Assogna F, Cravello L, Langella R, Caltagirone C, Spalletta G, Pontieri FE (2015) Neuropsychiatric and cognitive symptoms and body side of onset of parkinsonism in unmedicated Parkinson’s disease patients. Parkinsonism Relat Disord 21(9):1096–1100PubMedCrossRefGoogle Scholar
  139. Péran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, Celsis P, Rascol O, Démonet JF, Stefani A, Pierantozzi M, Pontieri FE, Caltagirone C, Spalletta G, Sabatini U (2010) Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature. Brain 133:3423–3433PubMedCrossRefGoogle Scholar
  140. Perju-Dumbrava LD, Kovacs GG, Pirker S, Jellinger K, Hoffmann M, Asenbaum S, Pirker W (2012) Dopamine transporter imaging in autopsy-confirmed Parkinson’s disease and multiple system atrophy. Mov Disord 27:65–71PubMedCrossRefGoogle Scholar
  141. Perlmutter JS, Norris SA (2014) Neuroimaging biomarkers for Parkinson disease: facts and fantasy. Ann Neurol 76:769–783PubMedPubMedCentralCrossRefGoogle Scholar
  142. Picard F, de Saint-Martin A, Salmon E, Hirsch E, Marescaux C (1996) Postencephalitic stereotyped involuntary movements responsive to l-dopa. Mov Disord 11(5):567–570PubMedCrossRefGoogle Scholar
  143. Poletti M, Frosini D, Pagni C, Baldacci F, Giuntini M, Mazzucchi S, Tognoni G, Lucetti C, Del Dotto P, Ceravolo R, Bonuccelli U (2013) The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naive patients with Parkinson’s disease. J Clin Exp Neuropsychol 35:124–131PubMedCrossRefGoogle Scholar
  144. Prakash BD, Sitoh YY, Tan LC, Au WL (2012) Asymmetrical diffusion tensor imaging indices of the rostral substantia nigra in Parkinson’s disease. Parkinsonism Relat Disord 18:1029–1033PubMedCrossRefGoogle Scholar
  145. Pramstaller PP, Künig G, Leenders K, Kann M, Hedrich K, Vieregge P, Goetz CG, Klein C (2002) Parkin mutations in a patient with hemiparkinsonism-hemiatrophy: a clinical-genetic and PET study. Neurology 58(5):808–810 Retrieved from PubMedCrossRefGoogle Scholar
  146. Prasad S, Stezin A, Lenka A, George L, Saini J, Yadav R, Pal PK (2018) Three-dimensional neuromelanin sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease. Eur J Neurol 25(4):680–686.
  147. Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ, Lee VM, Brundin P (2016) Widespread transneuronal propagation of alpha-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease. J Exp Med 213:1759–1778PubMedPubMedCentralCrossRefGoogle Scholar
  148. Riederer P, Sian-Hülsmann J (2012) The significance of neuronal lateralisation in Parkinson’s disease. J Neural Transm (Vienna) 119:953–962CrossRefGoogle Scholar
  149. Rinne JO, Laihinen A, Rinne UK, Någren K, Bergman J, Ruotsalainen U (1993) PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson’s disease. Mov Disord 8:134–138PubMedCrossRefGoogle Scholar
  150. Rissanen E, Paavilainen T, Virta J, Marttila RJ, Rinne JO, Airas L (2010) Carbon monoxide poisoning-induced nigrostriatal dopaminergic dysfunction detected using positron emission tomography (PET). Neurotoxicology 31(4):403–407PubMedCrossRefGoogle Scholar
  151. Rolinski M, Griffanti L, Piccini P, Roussakis AA, Szewczyk-Krolikowski K, Menke RA, Quinnell T, Zaiwalla Z, Klein JC, Mackay CE, Hu MT (2016) Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson’s disease. Brain 139:2224–2234PubMedPubMedCentralCrossRefGoogle Scholar
  152. Rudow G, O'Brien R, Savonenko AV, Resnick SM, Zonderman AB, Pletnikova O, Marsh L, Dawson TM, Crain BJ, West MJ, Troncoso JC (2008) Morphometry of the human substantia nigra in ageing and Parkinson’s disease. Acta Neuropathol 115:461–470PubMedPubMedCentralCrossRefGoogle Scholar
  153. Santos MC, Campos LS, Guimarães RP, Piccinin CC, Azevedo PC, Piovesana LG, De Campos BM, Scarparo Amato-Filho AC, Cendes F, D’Abreu A (2016) Does side of onset influence the pattern of cerebral atrophy in Parkinson’s disease? Front Neurol 7:145PubMedPubMedCentralCrossRefGoogle Scholar
  154. Schendan HE, Amick MM, Cronin-Golomb A (2009) Role of a lateralized parietal-basal ganglia circuit in hierarchical pattern perception: evidence from Parkinson’s disease. Behav Neurosci 123(1):125–136PubMedPubMedCentralCrossRefGoogle Scholar
  155. Scherfler C, Seppi K, Mair KJ, Donnemiller E, Virgolini I, Wenning GK, Poewe W (2012) Left hemispheric predominance of nigrostriatal dysfunction in Parkinson’s disease. Brain 135:3348–3354PubMedCrossRefGoogle Scholar
  156. Schiesling C, Kieper N, Seidel K, Krüger R (2008) Review: familial Parkinson’s disease—genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathol Appl Neurobiol 34(3):255–271. PubMedCrossRefGoogle Scholar
  157. Schneider LH, Murphy RB, Coons EE (1982) Lateralization of striatal dopamine (D2) receptors in normal rats. Neurosci Lett 13(33(3)):281–284CrossRefGoogle Scholar
  158. Schonhaut DR, McMillan CT, Spina S, Dickerson BC, Siderowf A, Devous MD Sr, Tsai R, Winer J, Russell DS, Litvan I, Roberson ED, Seeley WW, Grinberg LT, Kramer JH, Miller BL, Pressman P, Nasrallah I, Baker SL, Gomperts SN, Johnson KA, Grossman M, Jagust WJ, Boxer AL, Rabinovici GD (2017) (18) F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study. Ann Neurol 82:622–634PubMedCrossRefGoogle Scholar
  159. Seraji-Bozorgzad N, Bao F, George E, Krstevska S, Gorden V, Chorostecki J, Santiago C, Zak I, Caon C, Khan O (2015) Longitudinal study of the substantia nigra in Parkinson disease: a high-field (1) H-MR spectroscopy imaging study. Mov Disord 30:1400–1404PubMedCrossRefGoogle Scholar
  160. Shi J, Liu J, Qu Q (2014) Handedness and dominant side of symptoms in Parkinson’s disease. Med Clin (Barc) 142:141–144CrossRefGoogle Scholar
  161. Snow BJ, Tooyama I, McGeer EG, Yamada T, Calne DB, Takahashi H, Kimura H (1993) Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34:324–330PubMedCrossRefGoogle Scholar
  162. Standring S, Gray H (2008) Gray’s anatomy: the anatomical basis of clinical practice. Churchill Livingstone/Elsevier, EdinburghGoogle Scholar
  163. Sun Y, Li J, Suckling J, Feng L (2017) Asymmetry of hemispheric network topology reveals dissociable processes between functional and structural brain connectome in community-living elders. Front Aging Neurosci 9:361PubMedPubMedCentralCrossRefGoogle Scholar
  164. Tanaka S, Kanzaki R, Yoshibayashi M, Kamiya T, Sugishita M (1999) Dichotic listening in patients with situs inversus: brain asymmetry and situs asymmetry. Neuropsychologia 37(7):869–874. PubMedCrossRefGoogle Scholar
  165. Tang CC, Poston KL, Dhawan V, Eidelberg D (2010) Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson’s disease. J Neurosci 30(3):1049–1056PubMedPubMedCentralCrossRefGoogle Scholar
  166. Tanner JJ, Levy SA, Schwab NA, Hizel LP, Nguyen PT, Okun MS, Price CC (2017) Marked brain asymmetry with intact cognitive functioning in idiopathic Parkinson’s disease: a longitudinal analysis. Clin Neuropsychol 31:654–675PubMedCrossRefGoogle Scholar
  167. Tissingh G, Bergmans P, Booij J, Winogrodzka A, van Royen EA, Stoof JC, Wolters EC (1998) Drug-naive patients with Parkinson’s disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT. J Neurol 245:14–20PubMedCrossRefGoogle Scholar
  168. Toga AW, Thompson PM (2003) Mapping brain asymmetry. Nat Rev Neurosci 4:37–48PubMedCrossRefGoogle Scholar
  169. Tomer R, Levin BE, Weiner WJ (1993) Side of onset of motor symptoms influences cognition in Parkinson's disease. Ann Neurol 34(4):579–584PubMedCrossRefGoogle Scholar
  170. Uitti RJ, Baba Y, Whaley NR, Wszolek ZK, Putzke JD (2005) Parkinson disease: handedness predicts asymmetry. Neurology 64:1925–1930PubMedCrossRefGoogle Scholar
  171. Van Camp N, Vreys R, Van Laere K, Lauwers E, Beque D, Verhoye M, Casteels C, Verbruggen A, Debyser Z, Mortelmans L, Sijbers J, Nuyts J, Baekelandt V, Van der Linden A (2010) Morphologic and functional changes in the unilateral 6-hydroxydopamine lesion rat model for Parkinson’s disease discerned with microSPECT and quantitative MRI. MAGMA 23:65–75PubMedCrossRefGoogle Scholar
  172. van der Hoorn A, Burger H, Leenders KL, de Jong BM (2012) Handedness correlates with the dominant Parkinson side: a systematic review and meta-analysis. Mov Disord 27:206–210PubMedCrossRefGoogle Scholar
  173. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP (2001) [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson’s disease and multiple system atrophy. Mov Disord 16:1023–1032PubMedCrossRefGoogle Scholar
  174. Vilas D, Segura B, Baggio HC, Pont-Sunyer C, Compta Y, Valldeoriola F, José Martí M, Quintana M, Bayés A, Hernández-Vara J, Calopa M, Aguilar M, Junqué C, Tolosa E, the Barcelona LRRK2 Study Group (2016) Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: a magnetic resonance imaging study. Mov Disord 31:1820–1828PubMedCrossRefGoogle Scholar
  175. Wang J, Yang QX, Sun X, Vesek J, Mosher Z, Vasavada M, Chu J, Kanekar S, Shivkumar V, Venkiteswaran K, Subramanian T (2015) MRI evaluation of asymmetry of nigrostriatal damage in the early stage of early-onset Parkinson’s disease. Parkinsonism Relat Disord 21:590–596PubMedCrossRefGoogle Scholar
  176. Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N (1995) Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 91:247–250PubMedCrossRefGoogle Scholar
  177. Wu T, Hou Y et al (2015) Lateralization of brain activity pattern during unilateral movement in Parkinson’s disease. Hum Brain Mapp 36:1878–1891PubMedCrossRefGoogle Scholar
  178. Wu T, Hou Y, Hallett M, Zhang J, Chan P (2016) Proton MR spectroscopy for monitoring pathologic changes in the substantia nigra and globus pallidus in Parkinson disease. AJR Am J Roentgenol 206:385–389PubMedCrossRefGoogle Scholar
  179. Xu X, Wang Q, Zhang M (2008) Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study. NeuroImage 40(1):35–42PubMedCrossRefGoogle Scholar
  180. Yagi S, Yoshikawa E, Futatsubashi M, Yokokura M, Yoshihara Y, Torizuka T, Ouchi Y (2010) Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET. J Nucl Med 51:1250–1257PubMedCrossRefGoogle Scholar
  181. Yust-Katz S, Tesler D, Treves TA, Melamed E, Djaldetti R (2008) Handedness as a predictor of side of onset of Parkinson’s disease. Parkinsonism Relat Disord 14(8):633–635PubMedCrossRefGoogle Scholar
  182. Zheng Z, Poon WS (2017) Rodent model of Parkinson’s disease: unilateral or bilateral. J Alzheimers Dis Parkinsonism 7:2CrossRefGoogle Scholar
  183. Zhou B, Yuan F, He Z, Tan C (2014) Application of proton magnetic resonance spectroscopy on substantia nigra metabolites in Parkinson’s disease. Brain Imaging Behav 8:97–101PubMedCrossRefGoogle Scholar
  184. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44(4):601–607. PubMedCrossRefGoogle Scholar
  185. Zucco G, Zeni MT, Perrone A, Piccolo I (2001) Olfactory sensitivity in early-stage Parkinson patients affected by more marked unilateral disorder. Percept Mot Skills 92:894–898PubMedCrossRefGoogle Scholar
  186. Zucco GM, Rovatti F, Stevenson RJ (2015) Olfactory asymmetric dysfunction in early Parkinson patients affected by unilateral disorder. Front Psychol 16(6):1020Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • P. Riederer
    • 1
    • 2
  • K. A. Jellinger
    • 3
  • P. Kolber
    • 4
  • G. Hipp
    • 4
  • J. Sian-Hülsmann
    • 5
  • R. Krüger
    • 4
  1. 1.Center of Mental Health, Clinic and Policlinic for Psychiatry, Psychosomatics and PsychotherapyUniversity Hospital WürzburgWürzburgGermany
  2. 2.Psychiatry Department of Clinical ResearchUniversity of Southern Denmark, Odense University HospitalOdense CDenmark
  3. 3.Institute of Clinical NeurobiologyViennaAustria
  4. 4.Parkinson Research ClinicCentre Hospitalier de LuxembourgLuxembourgLuxembourg
  5. 5.Department of Medical PhysiologyUniversity of NairobiNairobiKenya

Personalised recommendations